Human papilloma virus (HPV) is responsible for the most frequent sexually transmitted disease of viral origin. There are more than one hundred thousand people infected around the world and this virus leads to 600,000 new cases of cervical cancer each year and tens of thousands of young people and adults with early-stage recurrent respiratory papillomatosis.
Since HPV was identified as one of the causes of cervical cancer, various prevention measures have been developed, making this a controlled disease. Here we are looking at the first possible case of eradicating a cancer, although there is still a long road ahead.
During these workshops, a multidisciplinary team from the field of HPV and cancer will discuss the complex factors that may affect the introduction of HPV vaccines and will design strategies to prevent cervical and other cancers related to the human papilloma virus.
The debates will feature researchers and professionals from various disciplines of science and medicine, including public health, virology, oncology, immunology, cell and molecular biology, and vaccine development. Experts and opinion leaders in health policy from key regions like Sub-Saharan Africa, Eastern Europe, the Middle East and Israel will also participate.